[How I Treat Myelodysplastic Symdromes]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2017 May 4

PMID 28468085

Authors

Z J Xiao

Affiliations

Soon will be listed here.

References

Santini V . Anemia as the Main Manifestation of Myelodysplastic Syndromes. Semin Hematol. 2015; 52(4):348-56. DOI: 10.1053/j.seminhematol.2015.06.002. View

Platzbecker U, Mufti G . Allogeneic stem cell transplantation in MDS: how? When?. Best Pract Res Clin Haematol. 2014; 26(4):421-9. DOI: 10.1016/j.beha.2013.09.008. View

Wang Y, Wang H, Lai Y, Sun Z, Wu D, Jiang M . Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016; 30(10):2055-2063. DOI: 10.1038/leu.2016.110. View

Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G . A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia. 2007; 22(3):538-43. DOI: 10.1038/sj.leu.2405070. View

Gyurkocza B, Deeg H . Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?. Blood Rev. 2012; 26(6):247-54. PMC: 3509173. DOI: 10.1016/j.blre.2012.08.002. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Killick S, Carter C, Culligan D, Dalley C, Das-Gupta E, Drummond M . Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2013; 164(4):503-25. DOI: 10.1111/bjh.12694. View

Cutler C, Lee S, Greenberg P, Deeg H, Perez W, Anasetti C . A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579-85. DOI: 10.1182/blood-2004-01-0338. View

Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl I, Dybedal I . A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003; 120(6):1037-46. DOI: 10.1046/j.1365-2141.2003.04153.x. View

10.

Greenberg P, Cox C, LeBeau M, Fenaux P, Morel P, Sanz G . International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88. View

11.

Li Y, Qin T, Xu Z, Zhang Y, Fang L, Zhang H . [Prognostic evaluation of comorbidities in patients with myelodysplastic syndrome]. Zhonghua Xue Ye Xue Za Zhi. 2015; 36(3):196-201. PMC: 7342508. DOI: 10.3760/cma.j.issn.0253-2727.2015.03.005. View

12.

Xiao Z . [Pay great attention to the diagnosis and treatment of iron overload in myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi. 2012; 32(8):505-6. View

13.

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

14.

Fenaux P, Haase D, Sanz G, Santini V, Buske C . Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii57-69. DOI: 10.1093/annonc/mdu180. View